The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2018 | PEP-C for treatment of relapsed/refractory lymphoma
The treatment of relapsed/refractory lymphoma can prove to be challenging. PEP-C (prednisone, etoposide, procarbazine, and cyclophosphamide) is an oral combination therapy regimen used for such patients. Here, George Follows, MA, BM, BCh, PhD, FRCP, FRCPath, from Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, discusses the Cambridge University Hospitals and Anglia regional experience of the benefits of using PEP-C over the past 8 years. This interview was recorded at the British society for Hematology (BSH) 2018 Annual Scientific Meeting, in Liverpool, UK.
